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Impaired in vivo antibody production in CRF rats: Role of secondary
hyperparathyroidism. Antibody responses to antigens are impaired in
humans and animals with chronic renal failure (CRF), and parathyroid
hormone (PTH) inhibits Staphylococcus aureus Cowan I (SAC) or
pokeweed mitogen (PWM)-induced antibody production by B cells
from normal subjects. Since CRF is associated with secondary hyper-
parathyroidism and elevated blood levels of PTH, it is possible that
impaired humoral immunity in CRF is due to chronic excess of PTH. To
test this hypothesis we examined in vivo antibody production in
response to sheep red blood cells (SRBC), BSA and influenza vaccine
in normal rats, CRF rats and parathyroidectomized CRF rats main-
tained normocalcemic (CRF-PTX). The blood levels of PTH in CRF
rats were elevated and significantly (P < 0.01) higher than those in
normal and CRF-PTX rats. The latter groups of animals did not have
elevated blood levels of PTH. The antibody response to all three
antigens in CRF rats were significantly (P < 0.01) and markedly lower
than in normal or CRF-PTX rats. The antibody response to SRBC, the
IgG anti-BSA and the IgG and 1gM anti-influenza vaccine in CRF-PTX
rats were not different from normal, while the 1gM anti-BSA was lower
than in normal rats but higher than in CRF rats. The data demonstrate
that the state of secondary hyperparathyroidism of CRF plays a
paramount role in the genesis of impaired humoral immunity in CRF,
Available data suggest that humoral immunity may be im-
paired in patients with advanced chronic renal failure (CRF) [1].
Indeed, decreased antibody responses to tetanus toxoid [2],
influenza vaccine 13] and hepatitis B vaccine [4] in CRF patients
were reported. Also, Staphylococcus aureUs Cowan I (SAC)-
induced proliferation of B cells from uremic patients is impaired
[5, 6] and both SAC or pokeweed mitogen (PWM)-induced
immunoglobulin production by these cells are reduced [7].
Recent studies have demonstrated that similar derangements
in B cells' proliferation and function could be produced by
parathyroid hormone (PTH) [6, 71. These data have led to the
proposition that the state of secondary hyperparathyroidism of
CRF [8—10] could be, at least in part, responsible for B cell
dysfunction in CRF. However, these observations do not
provide definite proof for a role of excess PTH in the genesis of
the abnormality in the in vivo immunoglobulin production. It is
possible that other consequences of the uremic state and/or
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another, as yet unidentified factor, accumulates in the blood of
uremic patients and underlies the impaired humoral immunity.
To definitely incriminate excess PTH in the genesis of im-
paired humoral immunity in CRF, one must document that
reduced antibody production in response to antigens is normal
in a CRF state without excess PTH. The present study was
undertaken to examine this question.
Methods
Male Sprague-Dawley rats weighing 220 to 250 g were stud-
ied. They were fed normal diet (ICN Nutritional Biochemicals,
Cleveland, Ohio, USA) throughout the study and allowed to
drink ad libitum. CRF was produced by 5/6 nephrectomy. First,
the animals underwent a right partial nephrectomy through a
flank incision; a week later, the left kidney was removed.
Parathyroidectomy (PTX) was performed by electrocautary,
and the success of the procedure was ascertained by a decrease
in serum levels of calcium of at least 2 mgldl. The PTX rats were
allowed to freely drink water containing 5% calcium gluconate.
This procedure is adequate to normalize plasma calcium in PTX
rats. Seven days after PTX, the animals were subjected to 5/6
nephrectomy as described above.
Four weeks after the 5/6 nephrectomy, the animals were
subjected to one of the following three protocols: 1) the rats
received intraperitoneal injection of io sheep red blood cells
(SRBC)/100 g body weight; SRBC were purchased from Colo-
rado Serum Co., Denver, Colorado, USA; 2) the animals were
given intramuscular injection of 1.0 mg of bovine serum albu-
min (BSA; Sigma Chemical Co., St. Louis, Missouri, USA)
dissolved in complete Freund's adjuvant (Calbiochem Co., San
Diego, California, USA), or 3) the rats received intramuscular
injection of 0.5 ml of trivalent influenza virus vaccine (Wyeth-
Ayerst Laboratories, Philadelphia, Pennsylvania, USA). Blood
samples of 0.3 to 0.5 ml were obtained by cutting the tail (under
light ether anesthesia) on the day of the injection and every two
days thereafter for a period of 20 days. The animals were
sacrificed on day 20 after the injection of the antigen and blood
samples were collected. At the time of sacrifice the animals had
grown and their weight had increased. Normal rats were also
injected with SRBC, BSA or influenza vaccine, and 11 blood
samples were obtained as described above.
Antibodies for the three antigens were measured in all blood
samples. The estimation of the anti-SRBC antibody was made
by the evaluation of the hemagglutinin titer in serum [11]. SRBC
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in sterile Aisevere's solution (Colorado Serum Co.) were
washed three times with 0.9% NaC1 (2500 rpm, 10 mm) and 1%
suspension of SRBC in saline was prepared. The sera from the
rats were heated to 56°C for 30 minutes to inactivate comple-
ment. The individual aggiutinin titers were measured in round-
bottom 96-well microtiter plates (Flow Laboratories, MacLean,
Virginia, USA). Serial twofold dilutions (from 1:2 to 1:4096) of
sera were made with 0.9% NaCI in 0.1 ml volumes in the plate.
To each well, 0.1 ml of 1% SRBC was added and plates were
incubated at 37°C for one hour and were then observed for
hemagglutination. Positive reaction was confirmed by examin-
ing the wells with a microscope. The agglutinin titer was
expressed as log2 of the highest serum dilution giving positive
reaction. All sera were tested in duplicates. The variability did
not exceed 1 log2 of titer.
The IgG and 1gM levels in response to BSA were determined
by enzyme-linked immunosorbent assay (ELISA) [12]. Flat-
bottom, 96-well microtiter plates (Flow Labs) were first coated
with 0.1 ml of carbonate-bicarbonate buffer (pH 9.6) containing
0.1 mg/mi of BSA, and allowed to incubate at 37°C for one hour.
The plates were washed three times by soaking in 0.9% NaCI
solution containing 0.05% Tween 20 (Sigma) for two minutes.
Samples of serum were diluted 100 to 500 times with phosphate
buffered saline (PBS) (GIBCO, Grand Island, New York, USA)
containing 0.5% of gelatin (DIFCO, Detroit, Michigan, USA)
and 0.05% of Tween 20, and added to duplicate wells in a
volume of 0.1 ml and incubated at 37°C for 1.5 hours. A positive
reference serum with high levels of anti-BSA IgG and 1gM was
diluted 50, 100, 500, 1000 and 10000 times with PBS with 0.5%
gelatin and 0.05% Tween 20 and was used as a standard. The
concentration of anti-BSA antibodies in the standard serum was
arbitrarily assumed to be 100 relative units (EIU) per ml.
Aliquots of 0.1 ml of standard serum solutions were added
simultaneously with tested sera, so that each plate had its own
standard curve. The microplates were then washed again three
times with 0.9% NaCI-Tween, and samples of 0.1 ml of the
appropriate goat anti-rat immunoglobulin antibody conjugated
with horseradish peroxidase (Jackson ImmunoResearch Labo-
ratories, West Grove, Pennsylvania, USA) were added to the
wells. Stock solutions of the conjugated antibodies were diluted
with PBS containing 0.5% gelatin and 0.05% Tween 20 to 1:5000
for anti-IgM and 1:20000 for anti-IgG. The wells were incubated
for 1.5 hours at 37°C, and the contents were then discarded and
wells washed three times with NaC1-Tween solution. Samples
of 0.1 ml of 20 mg of 0-phenylene-diamine dihydrochioride
(OPD) (Sigma) in 50 ml of citric buffer were added to the wells
which were left in the dark for 10 minutes. The reaction was
terminated by the addition of 0.1 ml of 6 N H2S04. The optical
density of each well was measured with a Titertek Multiscan
Reader (Dynatech Laboratories, Alexandria, Virginia, USA) at
the wavelength of 490 nm. The actual concentrations of anti-
BSA antibodies were determined using the appropriate stan-
dard curve and expressed as relative units (EIU) per ml. The
interassay coefficient was 7.2% and the intraassay coefficient
was 4.2%.
The measurements of serum levels of 1gM and IgG in
response to influenza vaccine was made by ELISA. The pro-
cedure is similar in principle to that for the measurements of
1gM and IgG in response to BSA with certain modification [13].
The viral antigen was diluted 1:20 in carbonate-bicarbonate
buffer and 0.1 ml was added to the wells of the 96-well
microtiter plates. The plates were incubated overnight at 4°C,
then the contents of the plates were discarded and the uncoated
sites of the wells were blocked by the addition of 0.1 ml of 1%
BSA (Sigma) dissolved in distilled water. The plates were
incubated for 1.5 hours at 37°C and then the microplates were
washed three times by soaking for two minutes in 0.9% NaC1
solution containing 0.05% Tween 20. Samples of sera were
diluted 50 to 200 times with PBS containing 0.5% BSA and
0.05% Tween 20, and 0.1 ml were added to duplicate wells.
Simultaneously, 0.1 ml of standard reference serum was used,
and the rest of the procedure was similar to that described for
measurements of IgG and 1gM in response to BSA. The
anti-influenza virus antibody levels in tested sera were deter-
mined by comparing with the reference serum which was
arbitrarily assumed to contain 100 relative units (EIU) of
anti-influenza antibody per ml. The interassay coefficient for
IgG was 11.7%, and the intrassay 6.1% and for 1gM the values
were 13.1% and 8.3%, respectively.
The concentrations of plasma calcium were measured by
Perkin-Elmer atomic absorption spectrophotometer, model 503
(Perkin Elmer Corp., Norwalk, Connecticut, USA), and those
of posphorus and creatinine by Technicon autoanalyzer (Tech-
nicon Instrument Inc., Tarrytown, New York, USA). The
serum levels of PTH were determined. PTH levels in serum
were determined by INS-PTH immunoassay kit (Nichols Insti-
tute Diagnostics, San Juan Capistrano, California, USA). This
assay recognizes the aminoterminal fragment of PTH. The
lowest detectable level is 3 pg/mi. The interassay variation is
7.3% and the intraassay variation is 4%.
Data are presented as mean SE. Changes from baseline in
parameters with multiple measurements with time (antibody
levels) were evaluated by calculating the area under the curve
for each experiment utilizing the trapezoidal rule. The areas
under the curve as well as the data on body weight and blood
biochemical measurements were evaluated by one-way analysis
of variance and Tukey's HSD test was used for comparison
between groups.
Results
The results are presented in Table I and Figures 1 to 3. The
nephrectomy procedure resulted in a significant (P < 0.01) rise
in the plasma levels of creatinine with the values being two to
three times higher than normal. Although creatinine clearance
of the rats of the present study was not measured, previous
studies from our laboratory have shown that similar increment
in plasma creatinine levels produced by 5/6 nephrectomy re-
flected a significant decrement in the values of creatinine
clearance. There were no significant differences in the plasma
concentrations of calcium and phosphorus among the three
groups or rats injected with SRBC or BSA or influenza vaccine.
Serum levels of PTH in CRF rats were significantly (P < 0.01)
higher than in normal or CRF-PTX rats.
The SRBC-antibody levels began to rise by day 2 after the
injection of SRBC and reached their peak by day 6 and
remained elevated thereafter (Fig. 1). The area under the curve
of the SRBC in CRF rats (71 6.4 Log2 anti-SRBC titer• 20
days) was significantly lower (P < 0.01) than that in normal rats
(123 7.7 Log2 anti-SRBC titer. 20 days) or in CRF-PTX rats
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Table 1. Body weight and blood chemistry in three groups of animals studied with the various antigens
Body weight
g
Plasma mg/dl
Phosphorus
Serum
PTH pg/rn!Creatinine Calcium
Studies with SRBC (N = 10)
Normal 394 5.1 0.38 0.02 10.3 0.23 6.1 0.30 12 2.3
CRF 361 5.4 1.00 0,09a 10.6 0.20 5.9 0.30 32 45a
CRF-PTS 338 20.5 0.80 0.OSa 10.8 0.30 6.3 0.14 Il 1.1
Studies with BSA (N = 10)
Normal 365 14.6 0.38 0.02 9.9 0.20 6.2 0.26 12 2.3
CRF 312 15.9 1.00 0.lOa 10.0 0.41 6.7 0.38 28 2.9a
CRF-PTX 333 12.0 0.97 0.l2 10.5 0.27 6.3 0.36 12 3.0
Studies with influenza vaccine (N = 10)
Normal 320 3.3 0.43 0.07 9.8 0.10 6.7 0.26 12 2.3
CRF 299 17.3 1.2 0.21 10.2 0.36 6.8 0.33 29 3.8a
CRF-PTX 317 8.1 1.2 0.l9 9.4 0.32 7.2 0.22 13 2.8
Data are presented as mean sa.
a P < 0.01 from other groups.
(110 7.2 Log2 anti-SRBC titer 20 days). The values between
the latter two groups were not significantly different.
Figure 2 depicts the serum levels of anti-BSA IgG and 1gM in
the three groups of animals. The anti-BSA IgG levels began to
rise on day 8 after the injection of BSA, peaked at day 12 and
plateaued thereafter. The production of anti-BSA IgG was
markedly and significantly impaired in CRF rats but was normal
in CRF.-PTX animals. The area under the curve in CRF animals
(240 48 EIU/mI . 20 days) was dignificantly (P <0.01) lower
than that in normal (870 110 EIU/ml . 20 days) or in CRF-
PTX (799 113 EIU/mI . 20 days) rats. The values between
normal and CRF-PTX rats were not different. The anti-BSA
1gM levels began to rise on day 6, reached their peaks on day 12
and declined thereafter. Again, the anti-BSA 1gM response in
CRF rats was markedly and significantly impaired in CRF rats,
and PTX of CRF rats was associated with a significant and
marked improvement in anti-BSA 1gM levels. The area under
the curve in CRF rats (242 24 EIU/mi . 20 days) was
significantly (P < 0.01) lower than that in normal (1484 137
EIU/mi . 20days) or in CRF-PTX (862 129 EIU/mI . 20 days)
rats. However, the value in CRF-PTX rats was still significantly
(P <0.01) lower than that in normal animals.
The changes in the serum levels of anti-influenza IgG and 1gM
are depicted in Figure 3. The IgG levels began to rise between
days 4 and 8 after the injection of the vaccine, peaked on day 14
and plateaued/or decreased thereafter. Again the IgG response
in CRF rats was significantly impaired. The area under the
curve in CRF rats (544 81 EIU/mi . 20 days) was significantly
(P < 0.01) lower than in normal (1178 64 EIU/mi . 20 days) or
CRF-PTX (968 116 EIU/mI . 20 days). The values between
the latter two groups were not significantly different. A similar
pattern was observed in the response of anti-influenza 1gM. In
the CRF rats the area under the curve (604 62 EIU/mI . 20
days) was significantly (P < 0.01) lower than in normal (1500
100 EIU/mi . 20 days) or in CRF-PTX (1494 244 EIU/ml 20
days) rats.
Discussion
The results of the present study demonstrate that the serum
levels of antibodies in response to SRBC, BSA and influenza
vaccine is markedly and significantly impaired in rats with CRF
and elevated blood levels of PTH. Further, this abnormality
was corrected or markedly ameliorated (1gM in response to
BSA) by prior PTX of CRF rats maintained normocalcemic.
These observations indicate that the state of secondary hyper-
parathyroidism and the elevated blood levels of PTH play a
major role in the genesis of the lower serum levels of immuno-
globulin in CRF in response to variouis antigens. These low
levels of immunoglobulin in CRF could be due to decreased
production or increased clearance of the antibodies and/or
quick removal of the antigen. CRF is a wasting state and is not
infrequently associated with malnutrition [141, and it has been
suggested that excess PTH may participate in the genesis of
increased catabolism of CRF (15]. It should be mentioned that
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Fig. 1. Serum levels of anti-SRBC titer in the three groups of rats.
Symbols are: (U) normal; (U) CRF; (0) CRF-PTX. Each datum point
represents the mean of studies in 10 rats and brackets denote I SE.
The values in CRF rats are lower (P < 0.05 - <0.01) than in normal and
CRF-PTX animals from days 8 to 18. On day 20 the values in CRF and
CRF-PTX rats are not different and the value in CRF-PTX rats is lower
than in normal rats (P < 0.05).
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Fig. 2. Serum levels of anti-BSA-IgG and anti-BSA-IgM in the three
groups of animals. Symbols are: (0) normal; (U) CRF; (0) CRF-PTX.
Each datum point represents the mean of studies in 10 rats and brackets
denote 1 SE. The values for IgG in CRF rats are lower (P < 0.01) than
in normal or CRF-PTX animals from days 8 to 20. There were no
significant differences between the values in normal and CRF-PTX rats.
The values for 1gM in CRF rats are lower (P < 0.01) than normal and
CRF-PTX animals from days 6 to 20. The values in CRF-PTX rats are
lower (P < 0.01) than normal from days 10 to 16.
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Fig. 3. Serum levels of anti-influenza (INFV) IgG and anti-influenza
1gM in the three groups of rats. Symbols are: (0) normal; (U) CRF; (0)
CRF-PTX. Each datum point represents the mean of studies in 10 rats
and brackets denote 1 SE. The values of IgG in CRF rats are lower (P
<0.05 - <0.01) than normal or CRF-PTX from days 8 to 20, except for
day 18 where the values between CRF and CRF-PTX rats are not
significantly different. The values between normal and CRF-PTX rats
are not different except on day 16. The values for 1gM in CRF rats were
lower (P < 0.01) than normal and CRF-PTX rats from days 4 to 20
except for day 10 and 16, The values between normal and CRF-PTX
rats were not different except for days 16 and 20 (P < 0.01).
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stable CRF is not a hypercatabolic state and any increase in
protein wasting under these circumstances is small [16]. How-
ever, if the wasting in CRF is associated with increased protein
degradation, it is possible that such a derangement also involves
various immunoglobulins leading to their increased removal. A
recent study by Lim et a! [17] showed that the catabolism of
CRF is characterized by a reduction in protein synthesis rather
than by increased protein degradation. It seems, therefore,
plausible to suggest that the reduced serum levels of immuno-
globulins in response to antigens in our CRF rats is due to a
decrease in their production. Further support for this notion is
provided by previous observations demonstrating that PTH
inhibits SAC or PWM-induced immunoglobulin production by
cultured B cells of normal subjects [7}. In any event, whether
excess PTH in CRF enhances removal of antigens and/or
immunoglobulins or decreases production of immunoglobulin in
response to antigens, it still remains the culprit responsible for
the low serum levels of the immunoglobulin in our CRF rats.
866 Gaciong et a!: In vivo antibody production in CRF
It is theoretically possible that some other, as yet unidenti-
fied, compound could also be present in the blood of the CRF
animals or humans, and it could contribute to impairment in
immunoglobulin production. However, this possibility seems
remote unless one postulates that the production and/or accu-
mulation of such a compound depends on the state of secondary
hyperparathyroidism. Even if such a possibility does exist, one
must still conclude that the excess blood levels of PTH are of
paramount importance in the genesis of the impaired humoral
immunity in CRF.
Our data provide an explanation for the observations in many
studies demonstrating impaired antibody production in re-
sponse to antigen such as tetanus toxoid [2], influenza vaccine
[3] or hepatitis B vaccine [4] in humans, or to BSA [181 in rats
with CRF, and for the findings of impaired SAC or PWM-
induced antibody production by B cells from dialysis patients
[7].
It should be mentioned that one study by Nelson et a! [19]
failed to demonstrate impaired antibody production in CRF
rats. These authors injected the antigen from day one of CRF
and followed antibody produciton for 28 days. In our studies we
began the injection of antigen after 28 days of CRF and followed
antibody production for additional 20 days. It is possible that
the differences between the results of Nelson et al [19] study
and ours are related to duration of CRF during which antibody
production was studied. The effects of PTH on antibody pro-
duction in response to SRBC was also studied by Swierenga
[20] et al. They found that PTX of normal rats before their
injection with SRBC was associated with impaired antibody
production, an observation that could be interpreted that lack of
PTH impairs the body response to antigens. Such an interpre-
tation appears to be contrary to our observation demonstrating
that excess PTH impairs antibody production. However, the
PTX rats of Swierenga et a! [20] were profoundly hypocalcemic
and it is plausible that their findings are related to the hypocal-
cemia rather than to lack of PTH.
We have previously shown that B cells are targets for PTH
action, and that the hormone inhibits SAC-induced proliferation
of B cells [6] as well as SAC or PWM-induced immunoglobulin
production [4]. The mechanisms underlying such an interaction
between PTH and B cells are multifactorial. PTH stimulates
cyclic AMP production by B cells [6], and cyclic AMP inhibits
antibody production [21—23]. The hormone enhances entry of
calcium into many cells [24—30] and may exert a similar effect
on B cells; such an action may inhibit antibody production.
Indeed, an acute rise in B cell calcium induced by A23 187
calcium ionophore was associated with impaired antibody pro-
duction [7]. Finally, chronic exposure to excess PTH, as in
CRF, is associated with a sustained rise in cytosolic calcium of
B cells [7]. Such an abnormality has been found to cause
dysfunction of many cell types [3 1—35], and it is reasonable to
suggest that a sustained rise in cytosolic calcium of B cells
adversely affects their function.
The results of the present study and other data from our
laboratory [6, 7] demonstrate that PTH satisfies most of the
criteria for a uremic toxin [36] in regard to its action on B cells
in CRF. Its blood levels are elevated, it affects B cell in vitro in
that it inhibits their proliferation and their antibody production,
the percent inhibition of SAC-induced proliferation of B cells
from dialysis patients by PTH is inversely related to the blood
levels of PTH of these patients, and the in vivo production of
antibody in response to antigen is normal in CRF without
secondary hyperparathyroidism.
We emphasize that we do not claim that excess PTH is the
sole factor underlying the impaired antibody production in
CRF. Indeed PTX did not entirely correct the 1gM production
to BSA. It seems that additional factors could also be operative
in CRF and such factors could also modulate the response to
antigens.
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